CN102574918A - 用于治疗与有害细胞增殖相关的疾病的治疗剂 - Google Patents

用于治疗与有害细胞增殖相关的疾病的治疗剂 Download PDF

Info

Publication number
CN102574918A
CN102574918A CN2010800246730A CN201080024673A CN102574918A CN 102574918 A CN102574918 A CN 102574918A CN 2010800246730 A CN2010800246730 A CN 2010800246730A CN 201080024673 A CN201080024673 A CN 201080024673A CN 102574918 A CN102574918 A CN 102574918A
Authority
CN
China
Prior art keywords
cytokines
cancer
lif
cell proliferation
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800246730A
Other languages
English (en)
Chinese (zh)
Inventor
琼·塞瓦内·苏亚雷斯
西尔维娅·佩纽拉斯·普列托
若泽·巴塞尔加·托里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Fundacio Institut de Recerca Hospital Universitari Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, Fundacio Institut de Recerca Hospital Universitari Vall dHebron filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Priority to CN201711070081.2A priority Critical patent/CN107964043A/zh
Publication of CN102574918A publication Critical patent/CN102574918A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
CN2010800246730A 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂 Pending CN102574918A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711070081.2A CN107964043A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ES200900928 2009-04-03
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711070081.2A Division CN107964043A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂

Publications (1)

Publication Number Publication Date
CN102574918A true CN102574918A (zh) 2012-07-11

Family

ID=42342718

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800246730A Pending CN102574918A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂
CN201711070081.2A Pending CN107964043A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711070081.2A Pending CN107964043A (zh) 2009-04-03 2010-04-06 用于治疗与有害细胞增殖相关的疾病的治疗剂

Country Status (24)

Country Link
US (4) US10100112B2 (enExample)
EP (2) EP3045474B1 (enExample)
JP (5) JP6207836B2 (enExample)
KR (6) KR20190093691A (enExample)
CN (2) CN102574918A (enExample)
AU (1) AU2010233791B2 (enExample)
BR (1) BRPI1015369A2 (enExample)
CA (1) CA2757680C (enExample)
CY (1) CY1124148T1 (enExample)
DK (1) DK3045474T3 (enExample)
EA (1) EA201101450A1 (enExample)
ES (2) ES2363358B1 (enExample)
HR (1) HRP20210352T1 (enExample)
HU (1) HUE054196T2 (enExample)
IL (1) IL215467A (enExample)
LT (1) LT3045474T (enExample)
MX (1) MX336903B (enExample)
PL (1) PL3045474T3 (enExample)
PT (1) PT3045474T (enExample)
SG (2) SG175032A1 (enExample)
SI (1) SI3045474T1 (enExample)
SM (1) SMT202100153T1 (enExample)
WO (1) WO2010115868A2 (enExample)
ZA (1) ZA201107215B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
CN113384686A (zh) * 2014-06-30 2021-09-14 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
CN114072173A (zh) * 2019-04-17 2022-02-18 国立大学法人广岛大学 以联合施用il-6抑制剂和ccr2抑制剂为特征的泌尿系统癌症治疗剂

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3117833B1 (en) * 2005-07-19 2019-01-23 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
AU2015228386A1 (en) * 2014-03-11 2016-09-22 Godavari Biorefineries Limited Cancer stem cell targeting compounds
CA2958685A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
MX2019007376A (es) 2016-12-19 2020-02-07 Mosaic Biomedicals S L U Anticuerpos contra el lif y usos de los mismos.
CN112638941A (zh) * 2018-05-14 2021-04-09 免疫医疗有限公司 针对lif的抗体及其剂量形式
JP7520727B2 (ja) * 2018-06-18 2024-07-23 メドイミューン・リミテッド 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法
WO2019243900A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572118A1 (en) * 1992-04-28 1993-12-01 Tosoh Corporation Monoclonal antibodies to GP130 protein
US5654157A (en) * 1992-05-08 1997-08-05 Genentech, Inc. Monoclonal antibodies to leukemia inhibitory factor and their use in immunoassays
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
CN101052717A (zh) * 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
JP2012501188A (ja) * 2008-08-29 2012-01-19 ジェネンテック， インコーポレイテッド Ｖｅｇｆ非依存性腫瘍についての診断薬および治療
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572118A1 (en) * 1992-04-28 1993-12-01 Tosoh Corporation Monoclonal antibodies to GP130 protein
US5654157A (en) * 1992-05-08 1997-08-05 Genentech, Inc. Monoclonal antibodies to leukemia inhibitory factor and their use in immunoassays
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
CN101052717A (zh) * 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FARHAD RAVANDI等: "The role of leukemia inhibitory factor in cancer and cancer metastasis", 《CANCER METASTASIS BIOLOGY AND TREATMENT GROWTH FACTORS AND THEIR RECEPTORS IN CANCER METASTASISI》 *
RAHAMAN SO等: "Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells", 《ONCOGENE》 *
SILVIA PENUELAS等: "TGF-β Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma", 《CANCER CELL》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113384686A (zh) * 2014-06-30 2021-09-14 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
CN114072173A (zh) * 2019-04-17 2022-02-18 国立大学法人广岛大学 以联合施用il-6抑制剂和ccr2抑制剂为特征的泌尿系统癌症治疗剂
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒

Also Published As

Publication number Publication date
US20120114671A1 (en) 2012-05-10
AU2010233791B2 (en) 2016-01-21
SG175032A1 (en) 2011-11-28
CA2757680C (en) 2021-11-02
US20200385455A1 (en) 2020-12-10
IL215467A0 (en) 2011-12-29
MX2011010425A (es) 2012-03-06
JP2019006784A (ja) 2019-01-17
PL3045474T3 (pl) 2021-08-09
WO2010115868A3 (en) 2011-02-03
US10100112B2 (en) 2018-10-16
KR20220035978A (ko) 2022-03-22
JP2020090522A (ja) 2020-06-11
DK3045474T3 (da) 2021-03-22
JP7197665B2 (ja) 2022-12-27
JP2012522756A (ja) 2012-09-27
SMT202100153T1 (it) 2021-05-07
CA2757680A1 (en) 2010-10-14
ES2363358A1 (es) 2011-08-01
SG10202010568RA (en) 2020-11-27
KR20180079470A (ko) 2018-07-10
HRP20210352T1 (hr) 2021-05-28
KR20170121319A (ko) 2017-11-01
JP6207836B2 (ja) 2017-10-04
KR20190093691A (ko) 2019-08-09
EA201101450A1 (ru) 2012-04-30
WO2010115868A2 (en) 2010-10-14
JP2016040255A (ja) 2016-03-24
PT3045474T (pt) 2021-03-22
JP2022031742A (ja) 2022-02-22
CN107964043A (zh) 2018-04-27
KR102373754B1 (ko) 2022-03-15
US11999782B2 (en) 2024-06-04
US20190211095A1 (en) 2019-07-11
EP3045474A2 (en) 2016-07-20
ES2363358B1 (es) 2012-06-21
IL215467A (en) 2016-06-30
US20240400667A1 (en) 2024-12-05
ES2864639T3 (es) 2021-10-14
EP3045474B1 (en) 2021-01-13
EP2414394A2 (en) 2012-02-08
KR20120100703A (ko) 2012-09-12
KR20200078668A (ko) 2020-07-01
LT3045474T (lt) 2021-05-10
SI3045474T1 (sl) 2021-07-30
CY1124148T1 (el) 2022-05-27
EP3045474A3 (en) 2016-09-28
HUE054196T2 (hu) 2021-08-30
MX336903B (es) 2016-02-04
ZA201107215B (en) 2012-12-27
AU2010233791A1 (en) 2011-11-03
BRPI1015369A2 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
JP7197665B2 (ja) 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP7410211B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338B (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EA040048B1 (ru) Фармацевтическая композиция и способ лечения глиомы, характеризущейся наличием высоких уровней lif

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172348

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120711

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172348

Country of ref document: HK